Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 425809 on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Females
NCT05613777Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iclepertin, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Ethinylestradiol in Plasma at Steady State Over a Uniform Dosing Interval τ at Day 21, Area Under the Concentration-time Curve of Levonorgestrel in Plasma at Steady State Over a Uniform Dosing Interval τ at Day 21 and 4 more. Started Nov 2022; status: completed.
02
Drugs
iclepertin
Beyond the preview
Go deeper on NCT05613777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613777.